FDAnews Drug Daily Bulletin
Oct. 8, 2012 | Vol. 9 No. 197
Apotex is taking the FDA to court for failing to grant timely approval of its ANDAs for two Sanofi hypertension treatments, Avapro and Avalide.
Amphastar Pharmaceuticals is slow to notify the FDA about complaints of serious and/or unexpected adverse events associated with its various generic drug products, a Form 483 states.
The FDA is in the last stages of finalizing a June 2011 guidance on classification of combination products, a senior FDA employee said Sept. 20.
Johnson & Johnson agreed to settle five lawsuits over claims that its antipsychotic drug Risperdal caused increased breast-tissue growth in boys.
FDA admits mistake with a generic drug, but it took too long, says ConsumerLab.com. Many lessons for consumers, doctors and pharmacists about generic drugs can be learned.
The 13-valent pneumococcal polysaccharide conjugate vaccine (Prevnar 13) elicits as strong an immune response in adults 18 to 49 as it does in those ages 60 to 64, according to Phase III results reported by Pfizer, the vaccine’s maker.
A steroid medication linked to the death of at least five people from rare fungal meningitis may have been administered to patients in 23 states, the U.S. Centers for Disease Control said, raising fears the rare outbreak could spread.
A Minnesota pharmaceutical company is merging with another drug company from Illinois in a deal that is valued at $95 million.
A Japanese pharmaceutical company is acquiring Bozeman-based LigoCyte Pharmaceuticals in a $60 million deal to expand its vaccine division, Takeda Pharmaceutical said.
ePublishing :: CMS, Hosting & Web Development | © Copyright by FDAnewsAll rights reserved. Do not duplicate or redistribute in any form.